Lisa Ricciardi
Known title: CEO & PresidentCIK: 0001418200
Lisa Ricciardi's purchase track record
How the stock did after each of Lisa Ricciardi's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since October 13, 2021
Stock higher 6 months later
20%
3 months: 40%
Median 6-month return
-34.0%
3 months: -15.3%
Beat the S&P 500
20%
median -43.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/16/2026 | CGTX | $10K | -15.3% | -34.0% | +10.0% |
| 1/31/2025 | CGTX | $30K | -38.3% | -7.8% | +3.3% |
| 3/14/2024 | CGTX | $10K | +23.6% | -66.1% | +8.6% |
| 11/15/2022 | CGTX | $16K | +25.5% | +15.9% | +3.0% |
| 10/13/2021 | CGTX | $150K | -48.7% | -76.4% | +1.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CGTX | ▲ Buy | Open Market | 9,175 | $10K | 4/16/2026 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 5,850 | $7K | 2/15/2026 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 51,704 | $53K | 2/4/2026 | View on chart |
| CGTX | ▲ Buy | Grant | 800,000 | $0 | 2/3/2026 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 26,036 | $29K | 2/3/2026 | View on chart |
| CGTX | ▲ Buy | Grant | 75,000 | $0 | 12/18/2025 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 23,400 | $35K | 12/18/2025 | View on chart |
| CGTX | ▲ Buy | Grant | 75,000 | $0 | 7/29/2025 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 23,400 | $16K | 7/29/2025 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 6,619 | $4K | 2/15/2025 | View on chart |
| CGTX | ▲ Buy | Grant | 631,300 | $0 | 2/4/2025 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 28,960 | $19K | 2/3/2025 | View on chart |
| CGTX | ▲ Buy | Open Market | 38,851 | $30K | 1/31/2025 | View on chart |
| CGTX | ▲ Buy | Open Market | 5,700 | $10K | 3/14/2024 | View on chart |
| CGTX | ▲ Buy | Grant | 75,000 | $0 | 2/15/2024 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 27,828 | $64K | 2/3/2024 | View on chart |
| CGTX | ▲ Buy | Grant | 213,973 | $0 | 2/3/2023 | View on chart |
| CGTX | ▲ Buy | Open Market | 12,000 | $16K | 11/15/2022 | View on chart |
| CGTX | ▲ Buy | Open Market | 12,500 | $150K | 10/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20
Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20. Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.